Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

This article was originally published here

GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is targeted to reduce the need for frequent intravitreal injections in retinal diseases, including wet AMD,

The post Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply